Parathyroid carcinoma: clinical presentation and management

Schoretsanitis, G; Daskalakis, Markos; Melissas, John; Tsiftsis, Dimitris D.

doi:10.1016/j.amjoto.2008.05.006

Cited by 25 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary hyperparathyroidism (HPT) is usually caused by a parathyroid adenoma, less commonly by parathyroid hyperplasia, and rarely by parathyroid carcinoma (0.5% to 5.2%) [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses

Cavaco

Santos²,

Félix

et al. 2011

Endocr Pathol

View full text Add to dashboard Cite

The diagnosis of parathyroid carcinomas is often difficult. HRPT2 mutations have been identified in familial [hyperparathyroidism-jaw tumor (HPT-JT) syndrome] and sporadic parathyroid carcinomas, supporting that HRPT2 mutations may confer a malignant potential to parathyroid tumors. In this study, we report the clinical, histopathological, and genetic investigation of two unrelated cases, whom had apparently sporadic malignant parathyroid tumors, initially diagnosed as adenomas. In one case, the differential diagnosis was complicated by cervical seeding of parathyroid tumor cells. Genetic studies identified de novo HRPT2 germline mutations in cases 1 (c.518_521delTGTC

show abstract

“…Primary hyperparathyroidism (HPT) is usually caused by a parathyroid adenoma, less commonly by parathyroid hyperplasia, and rarely by parathyroid carcinoma (0.5% to 5.2%) [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…The management of these aggressive neoplasms is primarily surgical, with en bloc tumor resection and ipsilateral thyroid lobectomy and resection of adjacent soft tissues being the recommended as mode of therapy [3][4][5][6]. However, the diagnosis of parathyroid carcinoma is often challenging.…”

Section: Introductionmentioning

confidence: 99%

Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses

Cavaco

Santos²,

Félix

et al. 2011

Endocr Pathol

View full text Add to dashboard Cite

show abstract

“…The overlap in symptoms between PCA and benign HPT makes it very challenging to differentiate between parathyroid adenoma and carcinoma on clinical grounds. Unfortunately, PCA most often is misdiagnosed as benign PHPT [44].…”

Section: Clinical Presentationmentioning

confidence: 99%

Parathyroid Carcinoma: Current Understanding and New Insights into Gene Expression and Intraoperative Parathyroid Hormone Kinetics

2010

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the association of parathyroid cancers with severe hypercalcemia and markedly elevated parathyroid hormone levels.2. Describe the effect of the risk factors, clinical presentation, and gene expression on diagnosis of parathyroid cancers.3. Analyze the probability of cure for parathyroid cancers with treatment by aggressive surgery with en bloc resection and lymph node dissection.This article is available for continuing medical education credit at CME.TheOncologist.com. The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. CME CME ABSTRACT EndocrinologyThe

show abstract

“…However, in patients with PC, they tend to occur more frequently and in more severe forms. Up to 15% of patients present with dehydration and/or altered mental status due to the hypercalcemia [36]. The clinical manifestations of the hypercalcemia from PC at presentation in several reported series are shown in Table 1 [8,[37][38][39][40][41].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Current Understanding and Management of Parathyroid Carcinoma

Arrangoiz¹

2017

JCTR

View full text Add to dashboard Cite

Parathyroid adenomas are a very common endocrine entity, whereas parathyroid carcinomas (PC) are extremely rare. With an estimated incidence of 0.015 per 100,000 population and an estimated prevalence of 0.005% in the United States, parathyroid cancer is one of the rarest of all human malignancies. PC is an extremely rare cause of primary hyperparathyroidism (PHPT). Men and women are equally affected, usually in the fourth or fifth decade of life. The exact etiology has not been identified, but mutations in the CDC73 gene appear to have a critical role in its pathogenesis. The morbidity and mortality of PC is secondary to the hypercalcemia resulting from tumor overproduction of PTH. The primary management objectives are complete removal of the cancer and prevention of recurrences. This review will talk about the epidemiology, etiology, clinical manifestations, and management of PC.

show abstract

Parathyroid carcinoma: clinical presentation and management

Cited by 25 publications

References 16 publications

Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses

Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses

Parathyroid Carcinoma: Current Understanding and New Insights into Gene Expression and Intraoperative Parathyroid Hormone Kinetics

Current Understanding and Management of Parathyroid Carcinoma

Contact Info

Product

Resources

About